Three milestones instrumental for all follow up developments expected second half of the year
VP oo1, data from larger animal studies - Data from larger animal studies are expected in the second half of 2021
Other novel ocular novel developments - PYC is cultivating a rich pipeline of novel development candidates to address additional ocular diseases. The Company expects to unveil additional development candidates for the treatment of high unmet need ocular indications during 2021.
CNS candidate
- Building on these data, the Company expects to nominate a candidate targeting a high unmet need neurodegenerative condition in 2021.
At some point during the next 6 weeks buying interest will appear and increase markedly until Oct, IMO.
Currently price is parked at very low base level, making this a strategic investment into the second part of the year.
all IMO
PYC Price at posting:
14.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)